The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study
Open accessAbstract
Objective: To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension. Design: Randomised multicentre trial over 48 weeks with double blind comparison of treatments. Setting: 48 centres in four countries. Patients: 868 patients with essential hypertension (diastolic blood pressure 95-120 mm Hg) Interventions: Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n=215), 25 mg atenolol (n=215), 10 mg nitrendipine (n=218), or 5 mg enalapril (n=220) once daily. If diastolic blood pressure was not reduced to <90 mm Hg within four weeks, doses were increased to 25 mg, 50 mg, 20 mg, 10 mg, respectively, once daily (step 2) and after two more weeks to twice daily (step 3). The eight week titration phase was followed by an additional 40 weeks for patients who had reached the target diastolic pressure. Main outcome measure: Blood pressure by means of an automatic device with repeated measurements. Results: After eight weeks the response rate for atenolol (63.7%) was significantly higher than for enalapril (50.0%), hydrochlorothiazide (44.7%), or nitrendipine (44.5%). After one year atenolol was still more effective (48.0%) than hydrochlorothiazide (35.4%) and nitrendipine (32.9%), but not significantly better than enalapril (42.7%). The treatment related dropout rate was higher (P<0.001) in the nitrendipine group (n=28). Conclusions: There is no evidence of superiority for antihypertensive effectiveness or tolerability of the “new” classes of antihypertensives (calcium channel blockers and angiotensin converting enzyme inhibitors). As these drugs are now widely used as treatment of first choice, our results further emphasise the need for studies confirming that they also reduce morbidity and mortality, as has been shown for diuretics and ß blockers. Key messages: Calcium channel blockers and angiotensin converting enzyme inhibitors as initial monotherapy in the treatment of hypertension Reduction in mortality has been shown only with established ß blockers and diuretics Comparison of treatment with hydrochlorothiazide, atenolol, nitrendipine, and enalapril showed no superiority of the new drug classes Atenolol was the most effective drug, while nitrendipine showed the highest drop out rat Elderly patients respond better to hydrochlorothiazide and nitrendipine, and women better to enalapril, although in both subgroups the highest rate of response was with atenolol
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Hassager, C., Riis, B. J., Strøm, V, Guyene, T. T., & Christiansen, C. (1987) · Circulation · doi:10.1161/01.cir.76.4.753 · Cited by 124
Cited by
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.033 · Cited by 1,075
Ramsay, L., Williams, B., Johnston, G., MacGregor, G., Poston, L., Potter, J., Poulter, N., Russell, G., & for the British Hypertension Society (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000917 · Cited by 585
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 474
First-line drugs for hypertension
Wright, J. M., Musini, V. M., & Gill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001841.pub3 · Cited by 452
British Hypertension Society guidelines for hypertension management 1999: summary
Ramsay, L. E., Williams, B., Johnston, G. D., MacGregor, G. A., Poston, L., Potter, J. F., Poulter, N. R., & Russell, G. (1999) · BMJ · doi:10.1136/bmj.319.7210.630 · Cited by 373
Metadata
- Authors
- Philipp, T., Anlauf, M., Distler, A., Holzgreve, H., Michaelis, J., & Wellek, S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1997-07-19
- Volume
- 315
- Issue
- 7101
- Pages
- 154-159
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2107686400
- Cited by
- 168
- References
- 4
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. https://app.cochat.ai/papers/10.1136/bmj.315.7101.154
- The paper
- Philipp, T., Anlauf, M., Distler, A., Holzgreve, H., Michaelis, J., & Wellek, S. (1997). Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ. https://doi.org/10.1136/bmj.315.7101.154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.